P-Glycoprotein Inhibitors [MoA]: Side Effects & Safety Data for 55 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
P-Glycoprotein Inhibitors [MoA] includes 55 drugs with a combined 437,710 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
55
Drugs in Class
437,710
Combined Reports
All P-Glycoprotein Inhibitors [MoA] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| CYCLOSPORINE | Verkazia | 68,304 | 9,332 | 14,257 | 13.7% |
| VENETOCLAX | Venclexta | 53,724 | 15,763 | 20,812 | 29.3% |
| AMIODARONE | Amiodarone Hydrochloride | 25,143 | 3,845 | 13,711 | 15.3% |
| CANAGLIFLOZIN | INVOKANA | 24,411 | 544 | 9,503 | 2.2% |
| NILOTINIB | nilotinib | 23,171 | 4,543 | 4,846 | 19.6% |
| TICAGRELOR | Ticagrelor | 22,885 | 2,951 | 8,579 | 12.9% |
| RELUGOLIX | Orgovyx | 20,660 | 958 | 1,699 | 4.6% |
| MIRABEGRON | MIRABEGRON | 20,618 | 1,338 | 2,589 | 6.5% |
| CLARITHROMYCIN | Clarithromycin | 18,945 | 987 | 6,385 | 5.2% |
| RITONAVIR | Norvir | 11,980 | 1,190 | 2,925 | 9.9% |
| AVAPRITINIB | Ayvakit | 10,117 | 302 | 942 | 3.0% |
| CRIZOTINIB | Xalkori | 9,948 | 3,173 | 2,520 | 31.9% |
| RANOLAZINE | Ranolazine | 9,522 | 1,048 | 3,367 | 11.0% |
| SUVOREXANT | BELSOMRA | 9,413 | 219 | 572 | 2.3% |
| VERAPAMIL | Verapamil Hydrochloride | 9,320 | 2,630 | 3,576 | 28.2% |
| VEMURAFENIB | ZELBORAF | 8,562 | 1,040 | 2,368 | 12.1% |
| VOCLOSPORIN | LUPKYNIS | 7,106 | 36 | 637 | 0.5% |
| ELACESTRANT | ORSERDU | 6,935 | 525 | 843 | 7.6% |
| IVACAFTOR | Kalydeco | 6,735 | 291 | 3,756 | 4.3% |
| TUCATINIB | TUKYSA | 6,042 | 640 | 1,717 | 10.6% |
| KETOCONAZOLE | Ketoconazole | 5,571 | 132 | 330 | 2.4% |
| SAPROPTERIN | JAVYGTOR | 5,539 | 60 | 339 | 1.1% |
| ZONISAMIDE | Zonisamide | 4,764 | 299 | 1,424 | 6.3% |
| RIPRETINIB | QINLOCK | 4,432 | 465 | 948 | 10.5% |
| ITRACONAZOLE | Itraconazole | 4,009 | 504 | 1,343 | 12.6% |
| LOMITAPIDE | Juxtapid | 3,779 | 109 | 434 | 2.9% |
| ELAGOLIX | Orilissa | 3,582 | 5 | 299 | 0.1% |
| SPARSENTAN | FILSPARI | 3,280 | 18 | 209 | 0.5% |
| ABROCITINIB | CIBINQO | 3,170 | 57 | 329 | 1.8% |
| DRONEDARONE | Multaq | 2,735 | 115 | 611 | 4.2% |
| PACRITINIB | Vonjo | 2,563 | 292 | 455 | 11.4% |
| CAPMATINIB | TABRECTA | 2,301 | 583 | 388 | 25.3% |
| ISAVUCONAZONIUM | CRESEMBA | 2,065 | 413 | 425 | 20.0% |
| ETRAVIRINE | Intelence | 1,969 | 257 | 405 | 13.1% |
| MARIBAVIR | Livtencity | 1,923 | 386 | 893 | 20.1% |
| FLIBANSERIN | ADDYI | 1,707 | 0 | 20 | N/A |
| ELIGLUSTAT | Cerdelga | 1,368 | 18 | 173 | 1.3% |
| VANDETANIB | CAPRELSA | 1,159 | 93 | 363 | 8.0% |
| ERDAFITINIB | BALVERSA | 1,106 | 315 | 226 | 28.5% |
| SELPERCATINIB | RETEVMO | 1,084 | 160 | 342 | 14.8% |
| ROLAPITANT | Varubi | 873 | 252 | 155 | 28.9% |
| PEMIGATINIB | PEMAZYRE | 709 | 121 | 185 | 17.1% |
| TEPOTINIB | TEPMETKO | 667 | 180 | 168 | 27.0% |
| MITAPIVAT | PYRUKYND | 627 | 4 | 58 | 0.6% |
| BEROTRALSTAT | Orladeyo | 548 | 24 | 128 | 4.4% |
| LENACAPAVIR | Sunlenca | 502 | 32 | 42 | 6.4% |
| SOTAGLIFLOZIN | INPEFA | 472 | 26 | 82 | 5.5% |
| PIRTOBRUTINIB | JAYPIRCA | 437 | 130 | 144 | 29.7% |
| COBICISTAT | Tybost | 347 | 41 | 109 | 11.8% |
| LEVOKETOCONAZOLE | Recorlev | 309 | 8 | 99 | 2.6% |
| VIMSELTINIB | ROMVIMZA | 170 | 0 | 5 | N/A |
| FUTIBATINIB | LYTGOBI | 161 | 38 | 60 | 23.6% |
| SARECYCLINE | Seysara | 134 | 0 | 11 | N/A |
| LONAFARNIB | Zokinvy | 59 | 6 | 14 | 10.2% |
| LEVACETYLLEUCINE | AQNEURSA | 48 | 1 | 1 | 2.1% |
Common Side Effects in P-Glycoprotein Inhibitors [MoA] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Drug ineffective | 34,173 | 2,966 |
| Off label use | 28,296 | 5,492 |
| Death | 24,936 | 24,858 |
| Fatigue | 24,660 | 1,727 |
| Nausea | 20,076 | 1,764 |
| Diarrhoea | 18,805 | 1,827 |
| Dyspnoea | 14,627 | 2,208 |
| Headache | 12,933 | 1,031 |
| Dizziness | 12,863 | 1,171 |
| Asthenia | 11,817 | 1,895 |